Item 5. Other Events.
Attached hereto as Exhibit A is a copy of the Registrant's
amended monthly operating report dated October 6, 1995 (the "Monthly
Operating Report"), to the United States Bankruptcy Court Trustee
for the District of Massachusetts, Western Division, relating to
the Registrant's petition under Chapter 11 of the United States
Bankruptcy Code, Case No. 94-43054-JFQ.
The Monthly Operating Report has not been audited by the
Registrant's independent, certified public accountants, nor does
the Monthly Operating Report contain complete consolidated
information relating to the Company's subsidiaries and affiliates
or adjustments which may be required as a result of an independent
audit of the Registrant's financial statements, including
adjustments relating to the special investigation described in the
Company's reports on Form 8-K filed with the Securities and
Exchange Commission on April 6, 1994 and May 13, 1994,
respectively.
Item 7. Exhibits.
The Registrant's Monthly Operating Report dated October 6, 1995
filed with the United States Bankruptcy Court Trustee for the
District of Massachusetts, Western Division, Case No. 94-43054-JFQ.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
behalf by the undersigned thereunto duly authorized.
CAMBRIDGE BIOTECH CORPORATION
Dated: October 6, 1995 By: \s\ Alison Taunton-Rigby
Alison Taunton-Rigby, President
UNITED STATES BANKRUPTCY COURT
EASTERN DISTRICT OF MASSACHUSETTS
IN RE: CAMBRIDGE BIOTECH CORPORATION CASE NO.: 94-43054-JFQ
365 PLANTATION STREET JUDGE: J.F. QUEENAN
WORCESTER, MA 01605-2376
DEBTOR(S): CAMBRIDGE BIOTECH CORPORATION, CHAPTER: 11
DEBTOR-IN-POSSESSION
MONTHLY OPERATING REPORT FOR MONTH ENDING: AUGUST 31, 1995
COMES NOW, CAMBRIDGE BIOTECH CORPORATION
Debtor-in-Possession, and hereby submits its Monthly Operating
Report for the period commencing August 1, 1995 and ending August 31,
1995 as shown by the report and exhibits consisting of twenty-one pages
and containing the following, as indicated:
____X____ Monthly Reporting Questionnaire (Attachment 1)
____X____ Comparative Balance Sheets (Forms OPR-1 & OPR-2)
____X____ Summary of Accounts Receivable (Form OPR-3)
____X____ Schedule of Post-petition Liabilities (Form OPR-4)
____X____ Income Statement (Form OPR-5)
____X____ Statement of Sources and Uses of Cash (Form OPR-6)
I declare under penalty of perjury that this report and all attachments
are true and correct to the best of my knowledge and belief.
Date: October 6, 1995 DEBTOR(S)-IN-POSSESSION
By: /s/ Alison Taunton-Rigby
Name & Title: Alison Taunton-Rigby
President & CEO
Address: 365 Plantation Street
Worcester, MA 01605-2376
Telephone No.:508-797-5777
Footnote:
As Debtor-in-Possession commenced filing on July 7, 1994
___________________________________________________________________________
Attachment 1 (Page 1)
Rev. 1/92
CHAPTER 11
MONTHLY OPERATING REPORT
MONTHLY REPORTING QUESTIONNAIRE
Case Name: CAMBRIDGE BIOTECH CORPORATION
Case Number: 94-43054
Month of: AUGUST 1, 1995 THROUGH AUGUST 31, 1995
1. Payroll: State the amount of all executive wages paid and taxes
withheld and paid.
See Attached
2. Insurance: Is worker's compensation and other insurance in effect? YES.
Are payments current? YES.
If any policy has lapsed, been replaced or renewed, state so
in the schedule below. Attach a copy of the new policy's
binder or cover page.
Date
Coverage
Carrier Coverage Expiration Premium Pd.
TYPE Name Amount Policy # Date Amounts Through
Homeowners
Rental
Property
Liability
Vehicle
Workers Comp(GA)
Workers Comp
(TX, FL, & CO)
Other
___________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054 SCHEDULE #1
Month of:
August, 1995
Monthly Operating Report - Wages - Executives
August 1 through August 31, 1995
Taxes Taxes Taxes
Name Title Gross Net Withheld Paid Due
A.Taunton-Rigby Pres./CEO 17,307.70 10,708.58 6,599.12 6,599.12 0.00
Jeffrey Beaver Chairman 7,692.32 4,888.93 2,803.39 2,803.39 0.00
Gary Long VP.Corp.Operations 9,615.40 6,794.41 2,820.99 2,820.99 0.00
Keith Jones (1)Corp.Controller 5,923.08 4,420.54 1,502.54 1,502.54 0.00
Deborah Grabbe (2)VP.Regulatory 5,000.00 3,491.88 1,508.12 1,508.12 0.00
Gerald Beltz (2) V.P. R&D 5,384.62 3,985.75 1,398.87 1,398.87 0.00
Robert Kammer (2)VP.Medical Aff. 5,769.23 4,117.41 1,651.82 1,651.82 0.00
--------- --------- --------- --------- ----
Total Executive Payroll: 56,692.35 38,407.50 18,284.85 18,284.85 0.00
NOTES:
(1) Resigned as of Sept. 1, 1995
(2) Elected as an Executive Officer as of August 21, 1995 -
Gross salary is for 1 biweekly pay period only, reflecting
status as officer.
____________________________________________________________________________
Attachment 1 (Page 2)
Rev. 1/92
CHAPTER 11
MONTHLY OPERATING REPORT
DETAILED LISTING OF DISBURSEMENTS
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Month of: August 1, 1995 through August 31, 1995
3. Bank Accounts
ACCOUNT TYPE
OPERATING OPERATING PAYROLL PAYROLL
Bank Fleet First Nat'l Bank of Flagship
Name BOM Balt
G/L number 1.1113 2.1129 2.1124.1 1.1119.1
Account number 9372562275 175-8828-5 39-12388 1023381112
Beginning Book
Balance $222,896.42 ($ 45.94) $ 0.00 $15,299.96
PLUS: Deposits 2,381,652.67
LESS:Disbursements (1,305,094.19) ($1,049.05) (697,125.43)
Other:
Transfers In(Out) (766,934.43) $2,300.00 698,081.10
Investments (242,478.00)
------------ -------- ---------- ----------
Ending Book
Balance (1) $290,042.47 $1,205.01 $ 0.00 $16,255.63
========== ======= ========== ==========
____________________________________________________________________________
Attachment 1 (Page 2)
Rev. 1/92
CHAPTER 11
MONTHLY OPERATING REPORT
DETAILED LISTING OF DISBURSEMENTS
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Month of: August 1, 1995 through August 31, 1995
3. Bank Accounts
ACCOUNT TYPE
PAYROLL PETTY CASH TOTAL
Bank Name Nations Bank N/A
G/L number 2.1127 xx.1150
Account number 3933333731 N/A
Beginning Book
Balance $5,217.53 $1,068.57 $244,436.54
PLUS: Deposits 2,381,652.67
LESS: Disbursements (47,582.19) ( 1,038.10) (2,051,888.96)
Other:
Transfers In(Out) 65,121.90 1,431.43 0.00
Investments (242,478.00)
--------- ----------- -----------
Ending Book
Balance (1) $22,757.24 $1,461.90 $331,722.25
========= ========= ==========
(1) Cash balances exclude $6,215,932 of short term investments of excess
cash. The total cash and short term investments increased for the
month of August by $329,763 and increased since the 7/7/94 filing date
by $3,937,914.
_____________________________________________________________________________
ATTACHMENT 1(Page 2)
REV. 1/92
CHAPTER 11
MONTHLY OPERATING REPORT
DETAILED LISTING OF DISBURSEMENTS
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Month of: August 1, through August 31, 1995
4. Post Petition Payments: List any post-petition payments to professionals
and payments on pre-petition debts in the schedule below (attach
separate sheet if necessary).
Payments To/On Amount Date Check #
Professionals:
Bowditch & Dewey $ 20,741.00 8/10/95 71255
Bromberg & Sunstein 324.73 8/08/95 71194
Bromberg & Sunstein 474.69 8/15/95 71349
Brown,Rudnick,Freed & Gesmer 52,689.54 8/01/95 71072
Brown,Rudnick,Freed & Gesmer 76,722.70 8/02/95 71103
Coopers & Lybrand 16,250.00 8/02/95 71105
Coopers & Lybrand 18,750.00 8/16/95 71384
Hale & Dorr 2,734.12 8/08/95 71201
Musket Research Assoc. 5,000.00 8/01/95 71088
Sterne, Kessler, Goldstein 72,900.00 8/11/95 71307
Venable, Baetjer & Howard 1,283.00 8/24/95 71514
----------
Total (Professionals) $267,869.78
==========
Pre-Petition Debts:
For Priority Debt:
None $0.00
--------
0.00
For Secured Debt:
Norwest Capital Lease Payment (2.3505) 381.20 8/10/95 71278
-------
381.20
For Unsecured Debt:
None 0.00
-------
0.00
For Accrued Restructuring:
Rockville Retention Bonus
Payments (TMS) 42,270.10 8/15/95 wire transfer
--------
42,270.10
---------
Total (Pre-petition) $42,651.30
========
_____________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-1
Comparative Balance Sheets
As of: August 31, 1995
FILING
DATE 7/31/94 8/31/94 9/30/94
ASSETS
CURRENT ASSETS:
Cash $1,287,187 $771,969 $863,230 $744,627
Other Negotiable
Instruments (i.e.
Commercial Paper,
CD's, Repo's, etc.) 1,322,553 2,925,553 3,235,553 2,001,807
Accounts Receivable
(See OPR-3) 2,813,217 2,798,473 2,426,792 3,072,351
Less: Allowance for
doubtful accounts (159,413) (153,957) (156,702) (156,702)
Inventory, at lower
of cost or market 4,619,236 4,575,836 4,436,073 3,837,729
Prepaid Expenses and
Deposits 540,318 758,112 724,877 917,900
Other Receivables 38,793 68,301 19,737 81,504
---------- ---------- ---------- ----------
TOTAL CURRENT ASSETS 10,461,891 11,744,287 11,549,560 10,499,216
PROPERTY, PLANT AND
EQUIPMENT, AT COST 27,437,762 27,440,087 27,443,284 27,400,776
Less: Accumulated
Depreciation (13,006,471)(13,250,916) (13,518,839)(13,794,569)
NET PROPERTY, PLANT ---------- ---------- ---------- ----------
& EQUIP. 14,431,291 14,189,171 13,924,445 13,606,207
OTHER ASSETS
Investment in Foreign
Subsidiary & Interco.
Receivables 7,302,195 7,225,880 7,333,273 7,320,217
Equity Investments in
Minority Interests 2,698,719 2,698,719 2,698,719 2,448,719
Long term Notes
Receivable 120,000 120,000 120,000 120,000
Patents & Purchased
Technology, net 4,335,293 4,278,428 4,208,789 4,139,151
Misc. other assets 83,666 83,543 85,921 103,250
----------- ---------- ---------- ----------
NET OTHER ASSETS 14,539,873 14,406,570 14,446,702 14,131,337
---------- ---------- ---------- ----------
TOTAL ASSETS $39,433,055 $40,340,028 $39,920,707 $38,236,760
========== ========== ========== ==========
See Accompanying Notes to Financial Statements
________________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-1
Comparative Balance Sheets
As of: August 31, 1995
10/31/94 11/30/94 12/31/94 1/31/95
ASSETS
CURRENT ASSETS:
Cash $121,108 $1,978,464 $41,017 $70,469
Other Negotiable
Instruments (i.e.
Commercial Paper,
CD's, Repo's, etc.) 2,744,989 6,518,489 8,396,774 8,171,774
Accounts Receivable
(See OPR-3) 2,456,055 2,020,214 2,676,067 2,366,192
Less: Allowance for
doubtful accounts (154,965) (154,988) (150,200) (150,754)
Inventory, at lower
of cost or market 3,992,196 4,161,087 3,623,742 3,724,804
Prepaid Expenses and
Deposits 843,827 1,049,251 836,285 857,048
Other Receivables 112,983 65,389 92,624 78,022
---------- ---------- ---------- ----------
TOTAL CURRENT ASSETS 10,116,193 15,637,906 15,516,309 15,117,555
PROPERTY, PLANT AND
EQUIPMENT, AT COST 27,395,379 27,392,289 27,361,463 27,367,498
Less: Accumulated
Depreciation (14,056,613) (14,318,428)(14,526,151) (14,773,133)
NET PROPERTY, PLANT ---------- ---------- ---------- ----------
& EQUIP. 13,338,766 13,073,861 12,835,312 12,594,365
OTHER ASSETS
Investment in Foreign
Subsidiary & Interco.
Receivables 7,319,514 1,100 1,100 1,100
Equity Investments in
Minority Interests 2,448,719 2,393,118 2,084,547 2,084,547
Long term Notes
Receivable 120,000 120,000 0 0
Patents & Purchased
Technology, net 4,089,540 4,017,654 4,057,044 3,996,889
Misc. other assets 110,888 72,832 105,791 105,668
---------- --------- --------- ---------
NET OTHER ASSETS 14,088,661 6,604,704 6,248,482 6,188,204
---------- ---------- ---------- ----------
TOTAL ASSETS $37,543,620 $35,316,471 $34,600,103 $33,900,124
========== ========== ========== ==========
See Accompanying Notes to Financial Statements
________________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-1
Comparative Balance Sheets
As of: August 31, 1995
2/28/95 3/31/95 4/30/95
ASSETS
CURRENT ASSETS:
Cash ($155,657) $114,214 $73,689
Other Negotiable Instruments
(i.e., Commercial Paper, CD's 8,159,683 6,479,683 6,162,566
Repo's, etc.)
Accounts Receivable (See OPR-3) 2,489,859 2,902,506 2,792,862
Less: Allowance for doubtful accounts (151,583) (148,773) (155,829)
Inventory, at lower of cost or market 3,567,739 3,624,245 3,711,567
Prepaid Expenses and Deposits 931,831 1,198,892 1,229,568
Other Receivables 60,615 61,603 64,693
---------- ---------- ----------
TOTAL CURRENT ASSETS 14,902,487 14,232,370 13,879,116
PROPERTY, PLANT AND EQUIPMENT, AT COST 27,379,288 27,480,169 27,479,539
Less: Accumulated Depreciation (15,008,591) (15,241,885)(15,471,782)
---------- ---------- ----------
NET PROPERTY, PLANT & EQUIP. 12,370,697 12,238,284 12,007,757
OTHER ASSETS
Investment in Foreign
Subsidiary & Interco. Receivables 1,100 1,100 1,100
Equity Investments in
Minority Interests 2,084,547 2,084,547 2,084,547
Long term Notes Receivable 0 0 0
Patents & Purchased Technology, net 3,943,189 3,900,274 3,854,572
Miscellaneous other assets 105,546 105,423 105,301
--------- --------- ---------
NET OTHER ASSETS 6,134,382 6,091,344 6,045,520
---------- ---------- ----------
TOTAL ASSETS $33,407,566 $32,561,998 $31,932,393
========== ========== ==========
See Accompanying Notes to Financial Statements
- -------------------------------------------------------------------
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-1
Comparative Balance Sheets
As of: August 31, 1995
ASSETS 5/31/95 6/30/95 7/31/95
CURRENT ASSETS:
Cash $57,900 $38,077 $244,437
Other Negotiable Instruments
(i.e. Commercial Paper, CD's
Repo's, etc.) 6,051,807 5,976,957 5,973,454
Accounts Receivable (See OPR-3) 2,804,766 3,122,119 2,972,550
Less: Allowance for doubtful accounts (159,019) (166,019) (173,017)
Inventory, at lower of cost or market 3,578,844 3,561,616 3,402,596
Prepaid Expenses and Deposits 1,261,826 1,234,929 1,163,646
Other Receivables 62,896 55,077 56,485
---------- ---------- ----------
TOTAL CURRENT ASSETS 13,659,020 13,822,756 13,640,151
PROPERTY, PLANT AND EQUIPMENT, AT COST 27,498,276 27,488,294 27,511,408
Less: Accumulated Depreciation (15,699,736) (15,899,373) (16,117,791)
---------- ---------- ----------
NET PROPERTY, PLANT & EQUIP. 11,798,540 11,588,921 11,393,617
OTHER ASSETS
Investment in Foreign
Subsidiary & Interco. Receivables 1,100 1,100 1,100
Equity Investments in
Minority Interests 2,084,547 2,084,547 2,084,547
Long term Notes Receivable 0 0 0
Patents & Purchased Technology, net 3,812,181 3,847,391 3,784,754
Miscellaneous other assets 105,179 105,056 104,934
--------- --------- ---------
NET OTHER ASSETS 6,003,007 6,038,094 5,975,335
---------- --------- ---------
TOTAL ASSETS $31,460,567 $31,449,771 $31,009,103
========== ========== ==========
See Accompanying Notes to Financial Statements
- ---------------------------------------------------------------------------
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-1
Comparative Balance Sheet
As of: August 31, 1995
ASSETS 8/31/95
CURRENT ASSETS:
Cash $331,722
Other Negotiable Instruments
(i.e. Commercial Paper, 6,215,932
CD's, Repo's etc.)
Accounts Receivable (See OPR-3) 2,744,188
Less:Allowance for doubtful
accounts (180,037)
Inventory, at lower of cost or
market 3,340,539
Prepaid Expenses and Deposits 1,360,141
Other Receivables 59,040
---------
TOTAL CURRENT ASSETS 13,871,525
PROPERTY, PLANT AND EQUIPMENT, AT COST 27,529,816
Less: Accumulated Depreciation (16,335,854)
-----------
NET PROPERTY, PLANT & EQUIP. 11,193,962
OTHER ASSETS:
Investment in Foreign Subsidiary
& Interco. Receivables 1,100
Equity Investments in Minority
Interests 2,084,547
Long Term Notes Receivable 0
Patents & Purchased Technology, net 3,740,765
Miscellaneous other assets 104,812
---------
NET OTHER ASSETS 5,931,224
---------
TOTAL ASSETS $30,996,711
==========
See Accompanying Notes to Financial Statements.
- ---------------------------------------------------------------------------
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-2
Comparative Balance Sheets
As of: August 31, 1995
FILING
DATE 7/31/94 8/31/94 9/30/94
LIABILITIES
POSTPETITION LIABILITIES (OPR-4) $0 $650,373 $1,141,051 $1,497,470
PRE PETITION LIABILITIES:
Priority Debt 223,302 182,012 182,012 68,035
Secured Debt 5,034,218 5,033,952 5,033,605 4,026,027
Unsecured Debt 5,693,250 5,694,993 5,694,993 5,725,313
TOTAL PRE PETITION ---------- ---------- ---------- ---------
LIABILITIES 10,950,770 10,910,957 10,910,610 9,819,375
Accrued Restructuring 1,844,180 1,842,293 1,838,952 1,838,649
Deferred Revenue & Taxes 2,735,700 2,729,262 2,705,941 2,663,591
---------- ---------- ---------- ----------
TOTAL LIABILITIES 15,530,650 16,132,885 16,596,554 15,819,085
SHAREHOLDERS' EQUITY (DEFICIT):
PREFERRED STOCK 0 0 0 0
COMMON STOCK 260,570 260,570 260,570 260,570
PAID - IN CAPITAL 119,978,714 119,985,005 119,993,131 120,001,257
ACCUMULATED DEFICIT:
Through Filing Date (96,336,879)(96,336,879)(96,336,879)(96,336,879)
Post Filing Date - 1994 298,447 (592,669) (1,507,273)
Post Filing Date - 1995
---------- ---------- ---------- ----------
TOTAL ACCUMULATED DEFICIT (96,336,879)(96,038,432)(96,929,548)(97,844,152)
---------- ---------- ---------- ----------
TOTAL SHAREHOLDERS' EQUITY 23,902,405 24,207,143 23,324,153 22,417,675
TOTAL LIABILITIES AND ---------- ---------- ---------- ----------
SHAREHOLDERS' EQUITY $39,433,055 $40,340,028 $39,920,707 $38,236,760
========== ========== ========== ==========
See Accompanying Notes to Financial Statements.
______________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-2
Comparative Balance Sheets
As of: August 31, 1995
10/31/94 11/30/94 12/31/94
LIABILITIES
POSTPETITION LIABILITIES (OPR-4) $2,082,362 $2,755,184 $3,094,624
PRE PETITION LIABILITIES:
Priority Debt 68,035 67,035 41,405
Secured Debt 4,025,674 4,025,320 4,024,962
Unsecured Debt 5,727,217 5,724,724 5,698,205
TOTAL PRE PETITION --------- --------- ---------
LIABILITIES 9,820,926 9,817,079 9,764,572
Accrued Restructuring 1,818,204 1,818,204 1,818,204
Deferred Revenue & Taxes 2,709,561 6,200,904 6,222,574
---------- ---------- ----------
TOTAL LIABILITIES 16,431,053 20,591,371 20,899,974
SHAREHOLDERS' EQUITY (DEFICIT):
PREFERRED STOCK 0 0 0
COMMON STOCK 260,570 260,570 260,570
PAID - IN CAPITAL 120,009,383 120,017,509 120,025,635
ACCUMULATED DEFICIT:
Through Filing Date (96,336,879) (96,336,879) (96,336,879)
Post Filing Date - 1994 (2,820,507) (9,216,100) (10,249,197)
Post Filing Date - 1995
---------- ----------- -----------
TOTAL ACCUMULATED DEFICIT (99,157,386)(105,552,979)(106,586,076)
---------- ---------- ----------
TOTAL SHAREHOLDERS' EQUITY 21,112,567 14,725,100 13,700,129
TOTAL LIABILITIES AND ---------- ---------- ----------
SHAREHOLDERS' EQUITY $37,543,620 $35,316,471 $34,600,103
========== ========== ==========
See Accompanying Notes to Financial Statements.
____________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-2
Comparative Balance Sheets
As of: August 31, 1995
1/31/95 2/28/95 3/31/95
LIABILITIES
POST PETITION LIABILITIES (OPR-4) $3,486,705 $3,792,060 $4,029,423
PRE PETITION LIABILITIES:
Priority Debt 41,405 41,405 37,685
Secured Debt 4,024,601 4,024,238 4,023,871
Unsecured Debt 5,657,221 5,663,260 5,659,724
--------- --------- ---------
TOTAL PRE PETITION LIABILITIES 9,723,227 9,728,903 9,721,280
Accrued Restructuring 1,818,204 1,814,597 1,811,938
Deferred Revenue & Taxes 5,915,588 5,522,460 5,150,121
---------- ---------- ----------
TOTAL LIABILITIES 20,943,724 20,858,020 20,712,762
SHAREHOLDERS' EQUITY (DEFICIT):
PREFERRED STOCK 0 0 0
COMMON STOCK 260,570 260,570 260,570
PAID - IN CAPITAL 120,033,760 120,041,887 120,050,013
ACCUMULATED DEFICIT:
Through Filing Date (96,336,879) (96,336,879) (96,336,879)
Post Filing Date - 1994 (10,249,197) (10,249,197) (10,249,197)
Post Filing Date - 1995 (751,854) (1,166,835) (1,875,271)
----------- ----------- -----------
TOTAL ACCUMULATED DEFICIT (107,337,930)(107,752,911)(108,461,347)
---------- ---------- ----------
TOTAL SHAREHOLDERS' EQUITY 12,956,400 12,549,546 11,849,236
TOTAL LIABILITIES AND ---------- ---------- ----------
SHAREHOLDERS' EQUITY $33,900,124 $33,407,566 $32,561,998
========== ========== ==========
See Accompanying Notes to Financial Statements.
____________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-2
Comparative Balance Sheets
As of: August 31, 1995
4/30/95 5/31/95 6/30/95
LIABILITIES
POST PETITION LIABILITIES (OPR-4) $4,138,912 $4,438,839 $4,952,436
PRE PETITION LIABILITIES:
Priority Debt 36,319 36,319 34,954
Secured Debt 4,023,502 4,023,129 4,022,754
Unsecured Debt 5,644,925 5,644,925 5,650,781
--------- --------- ---------
TOTAL PRE PETITION LIABILITIES 9,704,746 9,704,373 9,708,489
Accrued Restructuring 1,810,963 1,810,963 1,806,123
Deferred Revenue & Taxes 4,831,300 4,513,854 4,183,273
---------- ---------- ----------
TOTAL LIABILITIES 20,485,921 20,468,029 20,650,321
SHAREHOLDERS' EQUITY (DEFICIT):
PREFERRED STOCK 0 0 0
COMMON STOCK 260,570 260,570 260,570
PAID - IN CAPITAL 120,058,139 120,066,265 120,074,391
ACCUMULATED DEFICIT:
Through Filing Date (96,336,879) (96,336,879) (96,336,879)
Post Filing Date - 1994 (10,249,197) (10,249,197) (10,249,197)
Post Filing Date - 1995 (2,286,161) (2,748,221) (2,949,435)
----------- ----------- -----------
TOTAL ACCUMULATED DEFICIT (108,872,237)(109,334,297)(109,535,511)
---------- ---------- ----------
TOTAL SHAREHOLDERS' EQUITY 11,446,472 10,992,538 10,799,450
TOTAL LIABILITIES AND ---------- ---------- ----------
SHAREHOLDERS' EQUITY $31,932,393 $31,460,567 $31,449,771
========== ========== ==========
See Accompanying Notes to Financial Statements.
- -----------------------------------------------------------------------------
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-2
Comparative Balance Sheets
As of: August 31, 1995
7/31/95 8/31/95
LIABILITIES
POST PETITION LIABILITIES (OPR-4) $5,500,975 $5,673,349
PRE PETITION LIABILITIES:
Priority Debt 36,319 36,319
Secured Debt 4,022,376 4,021,995
Unsecured Debt 5,653,755 5,653,755
--------- ---------
TOTAL PRE PETITION LIABILITES 9,712,450 9,712,069
Accrued Restructuring 1,804,088 1,761,428
Deferred Revenue & Taxes 3,874,730 3,562,044
---------- ---------
TOTAL LIABILITES 20,892,243 20,708,890
SHAREHOLDERS' EQUITY (DEFICIT):
PREFERRED STOCK 0 0
COMMON STOCK 260,570 260,570
PAID - IN CAPITAL 120,074,391 120,074,391
ACCUMULATED DEFICIT:
Through Filing Date (96,336,879) (96,336,879)
Post Filing Date - 1994 (10,249,197) (10,249,197)
Post Filing Date - 1995 (3,632,025) (3,461,064)
----------- ------------
TOTAL ACCUMULATED DEFICIT (110,218,101)(110,047,140)
---------- ------------
TOTAL SHAREHOLDERS' EQUITY 10,116,860 10,287,821
TOTAL LIABILITIES AND ---------- -----------
SHAREHOLDERS' EQUITY $31,009,103 $30,996,711
========== ===========
See Accompanying Notes to Financial Statements.
____________________________________________________________________________
Case Name: Cambridge Biotech Corporation Form: OPR-3
Case Number: 94-43054
Summary of Accounts Receivable
As of: August 31, 1995
0 - 30 31 - 60
TOTAL DAYS DAYS
----------- ---------- ------------
Date of Filing:July 7, 1994 2,813,216.84 2,110,219.71 452,069.57
Allowance for doubtful accts (159,413.23)
Net 2,653,803.61 2,110,219.71 452,069.57
Month: July 31, 1994 2,798,472.98 1,289,104.11 1,238,841.68
Allowance for doubtful accts (153,956.56)
Net 2,644,516.42 1,289,104.11 1,238,841.68
Month: August 31, 1994 2,426,792.24 1,669,036.84 267,054.03
Allowance for doubtful accts (156,701.89)
Net 2,270,090.35 1,669,036.84 267,054.03
Month: Sept. 30, 1994 3,072,351.16 2,402,728.52 365,353.30
Allowance for doubtful accts (156,701.89)
Net 2,915,649.27 2,402,728.52 365,353.30
Month: October 31, 1994 2,456,054.54 1,406,348.28 750,784.77
Allowance for doubtful accts (154,964.89)
Net 2,301,089.65 1,406,348.28 750,784.77
Month: Nov. 30, 1994 2,020,214.59 1,322,881.77 350,696.71
Allowance for doubtful accts (154,988.00)
Net 1,865,226.59 1,322,881.77 350,696.71
Month: Dec. 31, 1994 2,676,067.46 2,057,744.50 389,515.89
Allowance for doubtful accts (150,200.00)
Net 2,525,867.46 2,057,744.50 389,515.89
Month: January 31, 1995 2,366,192.41 1,487,741.56 623,509.89
Allowance for doubtful accts (150,753.71)
Net 2,215,438.70 1,487,741.56 623,509.89
Month: Feb. 28, 1995 2,489,858.82 1,972,020.47 187,953.54
Allowance for doubtful accts (151,582.78)
Net 2,338,276.04 1,972,020.47 187,953.54
Month: March 31, 1995 2,902,506.56 2,061,722.33 671,660.83
Allowance for doubtful accts (148,773.14)
Net 2,753,733.42 2,061,722.33 671,660.83
Month: April 30, 1995 2,792,861.76 1,660,592.76 931,787.86
Allowance for doubtful accts (155,829.15)
Net 2,637,032.61 1,660,592.76 931,787.86
Month: May 31, 1995 2,804,766.36 2,153,951.07 257,035.14
Allowance for doubtful accts (159,019.25)
Net 2,645,747.11 2,153,951.07 257,035.14
Month: June 30, 1995 3,122,119.25 2,466,775.40 332,562.82
Allowance for doubtful accts (166,019.26)
Net 2,956,099.99 2,466,775.40 332,562.82
Month: July 31, 1995 2,972,550.36 2,212,905.66 547,650.93
Allowance for doubtful accts (173,017.12)
Net 2,799,533.24 2,212,905.66 547,650.93
Month: August 31, 1995 2,744,188.37 2,183,815.66 281,811.74
Allowance for doubtful accts. (180,037.08)
Net 2,564,151.29 2,183,815.66 281,811.74
_________________________________________________________________________
Case Name: Cambridge Biotech Corporation Form: OPR-3
Case Number: 94-43054
Summary of Accounts Receivable
As of: August 31, 1995
61 - 90 OVER
TOTAL DAYS 90 DAYS
----------- --------- ----------
Date of Filing:July 7, 1994 2,813,216.84 56,398.93 194,528.63
Allowance for doubtful accts (159,413.23) (159,413.23)
Net 2,653,803.61 56,398.93 35,115.40
Month: July 31, 1994 2,798,472.98 128,524.10 142,003.09
Allowance for doubtful accts (153,956.56) (11,953.47) (142,003.09)
Net 2,644,516.42 116,570.63 0.00
Month: August 31, 1994 2,426,792.24 297,637.99 193,063.38
Allowance for doubtful accts (156,701.89) (156,701.89)
Net 2,270,090.35 297,637.99 36,361.49
Month: Sept. 30, 1994 3,072,351.16 77,168.82 227,100.52
Allowance for doubtful accts (156,701.89) (156,701.89)
Net 2,915,649.27 77,168.82 70,398.63
Month: October 31, 1994 2,456,054.54 87,405.93 211,515.56
Allowance for doubtful accts (154,964.89) (154,964.89)
Net 2,301,089.65 87,405.93 56,550.67
Month: Nov. 30, 1994 2,020,214.59 188,381.49 158,254.62
Allowance for doubtful accts (154,988.00) (154,988.00)
Net 1,865,226.59 188,381.49 3,266.62
Month: Dec. 31, 1994 2,676,067.46 65,733.45 163,073.62
Allowance for doubtful accts (150,200.00) (150,200.00)
Net 2,525,867.46 65,733.45 12,873.62
Month: January 31, 1995 2,366,192.41 92,582.75 162,358.21
Allowance for doubtful accts (150,753.71) (150,753.71)
Net 2,215,438.70 92,582.75 11,604.50
Month: Feb. 28, 1995 2,489,858.82 176,471.97 153,412.84
Allowance for doubtful accts (151,582.78) (151,582.78)
Net 2,338,276.04 176,471.97 1,830.06
Month: March 31, 1995 2,902,506.56 45,696.46 123,426.94
Allowance for doubtful accts (148,773.14) (25,346.20) (123,426.94)
Net 2,753,733.42 20,350.26 0.00
Month: April 30, 1995 2,792,861.76 103,220.04 97,261.10
Allowance for doubtful accts (155,829.15) (58,568.05) (97,261.10)
Net 2,637,032.61 44,651.99 0.00
Month: May 31, 1995 2,804,766.36 313,259.39 80,520.76
Allowance for doubtful accts (159,019.25) (78,498.49) (80,520.76)
Net 2,645,747.11 234,760.90 0.00
Month: June 30, 1995 3,122,119.25 52,189.56 270,591.47
Allowance for doubtful accts (166,019.26) (166,019.26)
Net 2,956,099.99 52,189.56 104,572.21
Month: July 31, 1995 2,972,550.36 125,622.71 86,371.06
Allowance for doubtful accts (173,017.12) (86,646.06) (86,371.06)
Net 2,799,533.24 38,976.65 0.00
Month: August 31, 1995 2,744,188.37 123,876.76 154,684.21
Allowance for doubtful accts. (180,037.08) (25,352.87) (154,684.21)
Net 2,564,151.29 98,523.89 0.00
________________________________________________________________________
Case Name: Cambridge Biotech Corporation Form OPR-4
Case Number: 94-43054
Schedule of Post Petition Liabilities
As of: August 31, 1995
DATE DATE TOTAL 0-30 31-60
INCURRED DUE DUE DAYS DAYS
TAXES PAYABLE:
Federal Income Taxes W/H 0
FICA-Employer's Share 0
FICA-Employee's Share W/H 0
Unemployment Tax 0
State Income Tax Withheld 0
State Sales & Use Tax Various Various 4,345 4,345
State Franchise Tax Various Various 1,148 1,148
Real Estate and
Personal Property Tax Various Various 38,704 6,704 6,000
------ ------ -----
TOTAL TAXES PAYABLE 44,197 12,197 6,000
POST PETITION
SECURED DEBT 0 0
POST PETITION
UNSECURED DEBT 0 0
ACCRUED INTEREST
PAYABLE Various Various 437,607 33,113 33,345
TRADE ACCOUNTS
PAYABLE & OTHER:
Accounts Payable Various Various 686,592 555,788 89,460
Accrued Expenses Various Various 3,028,796 898,796 370,000
Accrued Stock
Incentive Plan 7/8/94 Emerge 1,476,157 1,476,157
from
Ch. 11
TOTAL ACCOUNTS --------- --------- -------
PAYABLE & OTHER 5,191,545 2,930,741 459,460
--------- --------- -------
TOTAL POST PETITION LIABILITIES $5,673,349 $2,976,051 $498,805
========= ========= =======
_______________________________________________________________________________
Case Name: Cambridge Biotech Corporation Form OPR-4
Case Number: 94-43054
Schedule of Post Petition Liabilities
As of: August 31, 1995
DATE DATE TOTAL 61-90 OVER 90
INCURRED DUE DUE DAYS DAYS
TAXES PAYABLE:
Federal Income Taxes W/H 0
FICA-Employer's Share 0
FICA-Employee's Share W/H 0
Unemployment Tax 0
State Income Tax Withheld 0
State Sales & Use Tax Various Various 4,345
State Franchise Tax Various Various 1,148
Real Estate and
Personal Property Tax Various Various 38,704 6,000 20,000
------ ----- -----
TOTAL TAXES PAYABLE 44,197 6,000 20,000
POST PETITION
SECURED DEBT 0 0
POST PETITION
UNSECURED DEBT 0 0
ACCRUED INTEREST
PAYABLE Various Various 437,607 32,932 338,217
TRADE ACCOUNTS
PAYABLE & OTHER:
Accounts Payable Various Various 686,592 1,410 39,934
Accrued Expenses Various Various 3,028,796 370,000 1,390,000
Accrued Stock
Incentive Plan 7/8/94 Emerge 1,476,157
from
Ch. 11
TOTAL ACCOUNTS --------- ------- ---------
PAYABLE & OTHER 5,191,545 371,410 1,429,934
--------- ------- ---------
TOTAL POST PETITION LIABILITIES $5,673,349 $410,342 $1,788,151
========= ======= =========
_____________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-5
Income Statement
Period: July 8, 1994 - August 31, 1995
7/8-31/94 August September
NET REVENUE (INCOME) $1,990,463 $1,297,330 $2,120,689
COST OF GOODS SOLD:
Materials
Labor - Direct
Manufacturing Overhead
TOTAL COST OF GOODS SOLD 677,628 872,453 1,424,705
--------- ------- -------
GROSS PROFIT 1,312,835 424,877 695,984
OPERATING EXPENSES:
Selling and Marketing 86,253 117,890 129,345
General and Administrative 330,964 404,625 548,839
Research and Development 223,590 359,735 288,595
Other: Regulatory 18,336 22,767 18,815
Other: Misc. (Income)/Expense (13,655) (8,694) (45,076)
------- ------- -------
TOTAL OPERATING EXPENSES 645,488 896,323 940,518
INCOME BEFORE INTEREST,
DEPRECIATION, TAXES OR ------- ------- -------
EXTRAORDINARY EXPENSES 667,347 (471,446) (244,534)
CHAPTER 11 EXPENSES (97,310) (113,110) (112,501)
INTEREST EXPENSE (27,145) (38,638) (31,839)
DEPRECIATION (244,445) (267,922) (275,730)
INCOME TAX EXPENSE 0 0 0
EXTRAORDINARY
INCOME(EXPENSE) 0 0 (250,000)
------- ------- -------
NET INCOME (LOSS) $298,447 ($891,116) ($914,604)
======= ======= =======
See Accompanying Notes to Financial Statements.
_______________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-5
Income Statement
Period: July 8, 1994 - August 31, 1995
October November December
NET REVENUE (INCOME) $1,089,394 $1,073,137 $1,938,051
COST OF GOODS SOLD:
Materials
Labor - Direct
Manufacturing Overhead
TOTAL COST OF GOODS SOLD 781,526 637,644 1,478,841
------- ------- -------
GROSS PROFIT 307,868 435,493 459,210
OPERATING EXPENSES:
Selling and Marketing 130,164 137,154 145,399
General and Administrative 503,279 497,797 445,169
Research and Development 526,086 376,756 505,667
Other: Regulatory 41,259 26,668 28,464
Other: Misc. (Income)/Expense 1,583 (28,619) (56,255)
--------- --------- ---------
TOTAL OPERATING EXPENSES 1,202,371 1,009,756 1,068,444
INCOME BEFORE INTEREST,
DEPRECIATION, TAXES OR ------- ------- -------
EXTRAORDINARY EXPENSES (894,503) (574,263) (609,234)
CHAPTER 11 EXPENSES (130,808) (105,473) (35,380)
INTEREST EXPENSE (25,880) (34,149) (32,395)
DEPRECIATION (262,043) (261,816) (245,061)
INCOME TAX EXPENSE 0 0 0
EXTRAORDINARY
INCOME(EXPENSE) 0 (5,419,892) (111,027)
--------- --------- ---------
NET INCOME (LOSS) $(1,313,234) $(6,395,593) $(1,033,097)
========= ========= =========
See Accompanying Notes to Financial Statements.
______________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-5
Income Statement
Period: July 8, 1994 - August 31, 1995
January 1995 February March
NET REVENUE (INCOME) $1,396,377 $1,881,536 $2,179,703
COST OF GOODS SOLD:
Materials
Labor - Direct
Manufacturing Overhead
TOTAL COST OF GOODS SOLD 823,876 987,069 1,062,214
------- ------- ---------
GROSS PROFIT 572,501 894,467 1,117,489
OPERATING EXPENSES:
Selling and Marketing 120,148 116,908 168,859
General and Administrative 433,681 451,508 633,552
Research and Development 404,257 395,094 687,899
Other: Regulatory 33,717 31,186 31,888
Other: Misc.
(Income)/Expense (52,814) (44,031) (42,176)
------- ------- ---------
TOTAL OPERATING EXPENSES 938,989 950,665 1,480,022
INCOME BEFORE INTEREST,
DEPRECIATION, TAXES OR ------- ------- -------
EXTRAORDINARY EXPENSES (366,488) (56,198) (362,533)
CHAPTER 11 EXPENSES (106,000) (96,420) (78,629)
INTEREST EXPENSE (32,384) (31,021) (33,980)
DEPRECIATION (246,982) (235,458) (233,294)
INCOME TAX EXPENSE 0 4,116 0
EXTRAORDINARY
INCOME(EXPENSE) 0 0 0
------- ------- -------
NET INCOME (LOSS) ($751,854) ($414,981) ($708,436)
======= ======= =======
See Accompanying Notes to Financial Statements.
_____________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-5
Income Statement
Period: July 8, 1994 - August 31, 1995
April May June
NET REVENUE (INCOME) $1,642,292 $2,188,446 $2,338,425
COST OF GOODS SOLD:
Materials
Labor - Direct
Manufacturing Overhead
TOTAL COST OF GOODS SOLD 794,369 1,154,352 1,162,791
------- --------- ---------
GROSS PROFIT 847,923 1,034,094 1,175,634
OPERATING EXPENSES:
Selling and Marketing 139,342 152,110 161,741
General and Administrative 395,543 572,129 415,455
Research and Development 392,539 408,496 452,840
Other: Regulatory 17,577 29,652 37,873
Other: Misc.
(Income)/Expense (48,350) (47,253) (74,391)
------- --------- -------
TOTAL OPERATING EXPENSES 896,651 1,115,134 993,518
INCOME BEFORE INTEREST,
DEPRECIATION, TAXES OR ------ ------ -------
EXTRAORDINARY EXPENSES (48,728) (81,040) 182,116
CHAPTER 11 EXPENSES (99,270) (113,541) (123,086)
INTEREST EXPENSE (32,995) (39,526) (32,996)
DEPRECIATION (229,897) (227,953) (227,248)
INCOME TAX EXPENSE 0 0 0
EXTRAORDINARY
INCOME(EXPENSE) 0 0 0
------- ------- -------
NET INCOME (LOSS) ($410,890) ($462,060) ($201,214)
======= ======= =======
See Accompanying Notes to Financial Statements.
- ----------------------------------------------------------------------------
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR - 5
Income Statement
Period: July 8, 1994 - August 31, 1995
FILING
July August TO DATE
NET REVENUE (INCOME) $1,938,622 $2,373,327 $25,447,792
COST OF GOODS SOLD:
Materials
Labor - Direct
Manufacturing Overhead
TOTAL COST OF GOODS SOLD 1,168,619 1,014,074 14,040,161
--------- --------- ----------
GROSS PROFIT 770,003 1,359,253 11,407,631
OPERATING EXPENSES:
Selling and Marketing 134,861 135,741 1,875,915
General and Administrative 446,284 330,294 6,409,119
Research and Development 498,460 397,805 5,917,819
Other: Regulatory 29,266 22,144 389,612
Other: Misc.
(Income)/Expense (47,012) (39,054) (545,797)
------- ------- ----------
TOTAL OPERATING EXPENSES 1,061,859 846,930 14,046,668
INCOME BEFORE INTEREST,
DEPRECIATION, TAXES OR ------- ------- ---------
EXTRAORDINARY EXPENSES (291,856) 512,323 (2,639,037)
CHAPTER 11 EXPENSES (138,916) (97,785) (1,448,229)
INTEREST EXPENSE (33,399) (25,514) (451,861)
DEPRECIATION (218,419) (218,063) (3,394,331)
INCOME TAX EXPENSE 0 0 4,116
EXTRAORDINARY
INCOME (EXPENSE) 0 0 (5,780,919)
------- -------- ---------
NET INCOME (LOSS) $(682,590) $170,961 $(13,710,261)
======= ======== ==========
See Accompanying Notes to Financial Statements.
_____________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-6
Statement of Sources and Uses of Cash
Period of: July 8, 1994 - August 31, 1995
July 8-
July 31 August September
SOURCES OF CASH:
Income (Loss) From Operations $298,447 ($891,116) ($914,604)
Add: Depreciation, Amortization
& Other Non-Cash Items 301,164 322,366 542,532
------- ------- -------
CASH GENERATED FROM OPERATIONS 599,611 (568,750) (372,072)
Add: Decrease in Assets:
Accounts Receivable 9,288 374,426
Other Receivables 48,564
Inventory 43,400 139,763 598,344
Prepaid Expenses & Deposits 33,235
Property, Plant & Equipment
Patents & Purchased Technology 18,612
Intercompany Receivables 76,315 13,056
Short Term Investments 1,233,746
Proceeds on sale of foreign
subsidiary
Proceeds on sale of minority interest
Proceeds on note receivable
Other non-current assets 123
Increase in Liabilities:
Pre-Petition Liabilities 1,742 52,055
Post-Petition Liabilities 650,372 490,679 356,419
Deferred Revenue
--------- ------- ---------
TOTAL SOURCES OF CASH (A) 1,380,851 517,917 1,900,160
USES OF CASH:
Increase in Assets:
Accounts Receivable 565,559
Other Receivables 29,508 61,767
Intercompany Receivables 107,393
Inventory
Prepaid Expenses & Deposits 217,794 193,023
Patents & Purchased Technology
Property, Plant & Equipment 2,325 3,197 37,492
Other non-current assets 2,378 17,329
Short Term Investments 1,603,000 310,000
Decrease in Liabilities:
Pre-Petition Liabilities 41,290 135,711
Post-Petition Liabilities
Accrued Restructuring 1,886 3,341 304
Secured Debt and Capital Leases 266 347 1,007,578
--------- ------- ---------
TOTAL USES OF CASH (B) 1,896,069 426,656 2,018,763
------- ------- -------
NET SOURCE (USE) OF CASH (A-B=NET) (515,218) 91,261 (118,603)
CASH - BEGINNING BALANCE (See OPR-1) 1,287,187 771,969 863,230
------- ------- -------
CASH - ENDING BALANCE (See OPR-1) $771,969 $863,230 $744,627
======= ======= =======
See Accompanying Notes to Financial Statements
_____________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-6
Statement of Sources and Uses of Cash
Period of: July 8, 1994 - August 31, 1995
October November December
SOURCES OF CASH:
Income (Loss) From Operations ($1,313,234)($6,395,593) ($1,033,097)
Add: Depreciation, Amortization
& Other Non-Cash Items 695,379 5,591,211 273,411
------- ------- -------
CASH GENERATED FROM OPERATIONS (617,855) (804,382) (759,686)
Add: Decrease in Assets:
Accounts Receivable 539,309 435,863
Other Receivables 47,594
Inventory 537,345
Prepaid Expenses & Deposits 74,073 212,966
Property, Plant & Equipment 80,647 3,090
Patents & Purchased Technology 18,612
Intercompany Receivables 703
Short Term Investments
Proceeds on sale of foreign
subsidiary 1,982,685
Proceeds on sale of minority interest 308,571
Proceeds on note receivable 120,000
Other non-current assets 38,056
Increase in Liabilities:
Pre-Petition Liabilities 1,904 230,000
Post-Petition Liabilities 168,807 557,512 243,428
Deferred Revenue 88,212 3,528,549 152,057
------- --------- -------
TOTAL SOURCES OF CASH (A) 335,800 6,037,579 814,681
USES OF CASH:
Increase in Assets:
Accounts Receivable 660,641
Other Receivables 31,479 27,235
Intercompany Receivables 28,561
Inventory 154,467 168,891
Prepaid Expenses & Deposits 205,424
Patents & Purchased Technology 1,756 93,988
Property, Plant & Equipment 6,513
Other non-current assets 7,638 32,959
Short Term Investments 743,182 3,773,500 1,878,285
Decrease in Liabilities:
Pre-Petition Liabilities 3,492 52,149
Post-Petition Liabilities
Accrued Restructuring 20,445
Secured Debt and Capital Leases 352 355 358
------- --------- ---------
TOTAL USES OF CASH (B) 959,319 4,180,223 2,752,128
------- --------- ---------
NET SOURCE (USE) OF CASH (A-B=NET) (623,519) 1,857,356 (1,937,447)
CASH - BEGINNING BALANCE (See OPR-1) 744,627 121,108 1,978,464
------- --------- -------
CASH - ENDING BALANCE (See OPR-1) $121,108 $1,978,464 $41,017
======= ========= =======
See Accompanying Notes to Financial Statements
____________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-6
Statement of Sources and Uses of Cash
Period of: July 8, 1994 - August 31, 1995
January February March
SOURCES OF CASH:
Income (Loss) From
Operations ($751,854) ($414,981) ($708,436)
Add: Depreciation,
Amortization & Other
Non-Cash Items 109,573 25,731 99,891
CASH GENERATED FROM ------- ------- -------
OPERATIONS (642,281) (389,250) (608,545)
Add: Decrease in Assets:
Accounts Receivable 310,429
Other Receivables 14,602 17,407
Inventory 157,065
Prepaid Expenses &
Deposits
Property, Plant &
Equipment
Patents & Purchased
Technology
Intercompany Receivables
Short Term Investments 225,000 12,091 1,680,000
Proceeds on sale of
foreign subsidiary
Proceeds on sale of
minority interest
Proceeds on note receivable
Other non-current assets
Increase in Liabilities:
Pre-Petition Liabilities 1,923
Post-Petition
Liabilities 290,907 194,519 67,032
Deferred Revenue
------- ------ ---------
TOTAL SOURCES OF CASH (A) 198,657 (6,245) 1,138,487
USES OF CASH:
Increase in Assets:
Accounts Receivable 122,838 415,457
Other Receivables 988
Intercompany Receivables
Inventory 101,062 56,506
Prepaid Expenses &
Deposits 20,763 74,783 267,061
Patents & Purchased
Technology 6,500 17,442
Property, Plant &
Equipment 6,035 11,790 100,880
Other non-current assets
Short Term Investments
Decrease in Liabilities:
Pre-Petition Liabilities 40,984 7,256
Post-Petition Liabilities
Accrued Restructuring 0 3,607 2,659
Secured Debt and
Capital Leases 361 363 367
------- ------- -------
TOTAL USES OF CASH (B) 169,205 219,881 868,616
NET SOURCE (USE) OF CASH
(A-B=NET) 29,452 (226,126) 269,871
CASH-BEGINNING BALANCE
(See OPR-1) 41,017 70,469 (155,657)
CASH-ENDING BALANCE ------ ------- -------
(See OPR-1) $70,469 ($155,657) $114,214
====== ======= =======
See Accompanying Notes to Financial Statements.
_____________________________________________________________________________
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR-6
Statement of Sources and Uses of Cash
Period of: July 8, 1994 - August 31, 1995
April May June
SOURCES OF CASH:
Income (Loss) From
Operations ($410,890) ($462,060) ($201,214)
Add: Depreciation,
Amortization & Other
Non-Cash Items 171,744 166,848 79,043
CASH GENERATED FROM ------- ------- -------
OPERATIONS (239,146) (295,212) (122,171)
Add: Decrease in Assets:
Accounts Receivable 116,700
Other Receivables 1,797 7,819
Inventory 132,723 17,228
Prepaid Expenses &
Deposits 26,897
Property, Plant &
Equipment 630
Patents & Purchased
Technology
Intercompany Receivables
Short Term Investments 317,117 110,759 74,850
Proceeds on sale of
foreign subsidiary
Proceeds on sale of
minority interest
Proceeds on note receivable
Other non-current assets
Increase in Liabilities:
Pre-Petition Liabilities 4,491
Post-Petition Liabilities 112,840 402,106
Deferred Revenue
------- ------ -------
TOTAL SOURCES OF CASH (A) 195,301 62,907 411,220
USES OF CASH:
Increase in Assets:
Accounts Receivable 8,714 310,353
Other Receivables 3,090
Intercompany Receivables
Inventory 87,322
Prepaid Expenses &
Deposits 30,676 32,257
Patents & Purchased
Technology 14,994 18,615 97,846
Property, Plant &
Equipment 18,737 17,629
Other non-current assets
Short Term Investments
Decrease in Liabilities:
Pre-Petition Liabilities 16,165
Post-Petition Liabilities 82,235
Accrued Restructuring 975 4,840
Secured Debt and
Capital Leases 369 373 375
------- ------ -------
TOTAL USES OF CASH (B) 235,826 78,696 431,043
NET SOURCE (USE) OF CASH ------ ------ ------
(A-B=NET) (40,525) (15,789) (19,823)
CASH-BEGINNING BALANCE
(See OPR-1) 114,214 73,689 57,900
CASH-ENDING BALANCE ------ ------ ------
(See OPR-1) $73,689 $57,900 $38,077
====== ====== ======
See Accompanying Notes to Financial Statements.
- -----------------------------------------------------------------------------
Case Name: Cambridge Biotech Corporation
Case Number: 94-43054
Form OPR - 6
Statement of Sources and Uses of Cash
Period of: July 8, 1994 - August 31, 1995
7/8/94 to
July August 8/31/95
SOURCES OF CASH: ------ ------- ---------
Income (Loss) From
Operations $(682,590) $170,961 $(13,710,261)
Add: Depreciation,
Amortization & Other
Non-Cash Items 1,241 (31,548) 8,348,586
CASH GENERATED FROM ------- -------- ---------
OPERATIONS (681,349) 139,413 (5,361,675)
Add: Decrease in Assets:
Accounts Receivables 156,567 235,382 2,177,964
Other Receivables 137,783
Inventory 159,020 62,057 1,846,945
Prepaid Expenses &
Deposits 71,283 418,454
Property, Plant &
Equipment 84,367
Patents & Purchased
Technology 37,224
Intercompany Receivables 90,074
Short Term Investments 3,503 3,657,066
Proceeds on sale of
foreign subsidiary 1,982,685
Proceeds on sale of
minority interest 308,571
Proceeds on note receivable 120,000
Other non-current assets 0 38,179
Increase in Liabilities:
Pre-Petition Liabilities 4,339 296,454
Post-Petition Liabilities 519,932 172,374 4,226,927
Deferred Revenue 3,768,818
------- ------- ---------
TOTAL SOURCES OF CASH (A) 233,295 609,226 13,829,836
USES OF CASH:
Increase in Assets:
Accounts Receivable 2,083,562
Other Receivables 1,408 2,555 158,030
Intercompany Receivables 135,954
Inventory 568,248
Prepaid Expenses &
Deposits 196,495 1,238,276
Patents & Purchased
Technology 18,964 270,105
Property, Plant &
Equipment 23,114 18,408 246,120
Other non-current assets 60,304
Short Term Investments 242,478 8,550,445
Decrease in Liabilities:
Pre-Petition Liabilities 297,047
Post-Petition Liabilities 82,235
Accrued Restructuring 2,035 42,660 82,752
Secured Debt and
Capital Leases 378 381 1,012,223
------ ------- ---------
TOTAL USES OF CASH (B) 26,935 521,941 14,785,301
NET SOURCE (USE) OF CASH ------- ------- -------
(A-B=NET) 206,360 87,285 (955,465)
CASH - BEGINNING BALANCE
(See OPR-1) 38,077 244,437 1,287,187
CASH - ENDING BALANCE ------- ------- ---------
(See OPR-1) $244,437 $331,722 $331,722
======= ======== =========
See Accompanying Notes to Financial Statements.
_____________________________________________________________________________
NOTES TO FINANCIAL STATEMENTS
1. The accompanying financial statements of Cambridge Biotech
Corporation (the Company) are for U.S. Operations only.
2. The Balance Sheet as of July 7, 1994, the date of the
Company's Chapter 11 filing, was restated in December 1994 to
reflect the Company's assets, liabilities, and shareholders'
equity after additional adjustments for subsequent
information. The assets increased by $233,432, liabilities
increased by $197,371, and shareholders' equity increased
by $36,061. The accumulated losses increased by $383.
3. The financial statements presented are unaudited and reflect
management's best judgment. Certain items which could have
an impact on the Company's financial statements are:
a. The Company's monthly inventory valuations and the amount of
reserves reflect management's best judgement. However, the
Company's auditors have not yet completed the December 31, 1994
year end audit, which when complete, may result in adjustments
to the year end inventory.
b. The Company has an investment in GRF Co. of $2,084,547
which represents a 19% interest in GRF Co. and is
accounted for by the cost method. When the Company filed
for protection under Chapter 11, GRF Co. ceased providing
information to the Company. Recently GRF Co. has agreed
to respond to the Company's requests and has provided some
information concerning activities of GRF Co. Initial review
of this information by the Company's scientific personnel
indicates a loss in the value of the investment, and the
Company presently expects that when its 1994 audited
financial statements are released, they will reflect a write
off in full of the carrying value of the investment.
c. The Company's investment in its Irish subsidiary,
Cambridge Biotech Limited (CBL), was adjusted prior to
the Company's Chapter 11 filing to its net tangible
asset value. On November 30, 1994, the Company sold CBL
to SelfCare, Inc. The Company originally reported in
its November financial statements a loss on the
disposition of CBL of $5,134,290. Subsequent to the
issuance of the November report, the loss amount was
increased in December to $5,475,317 as a result of the
inclusion of royalty obligations by the Company for
products sold by CBL utilizing certain licensed
technology. Calculation of the loss on this transaction
was based upon unaudited financial statements which
included estimates of the operating results of CBL through
November 30, 1994. When the Company's 1994 audit is complete,
the Company expects that the effective date of this transaction
will be changed to July 21, 1994 (the date CBL filed for
examinership). The change in the effective date of the
transaction will result in an adjustment to the reported loss
on the transaction.
d. In November 1994, the Company received $3.5 million as a
payment of a license fee originally due in January 1995
which was recorded as deferred revenue. Although the
Company's past practice with respect to this license
agreement was to recognize the entire annual payment as
revenue when due, management feels it is appropriate to
recognize the revenue ratably over 1995 at $291,667 per
month.
4. The Company entered into an agreement with BASF Bioresearch
Corporation for them to manufacture three batches of QS-21
product. The agreement calls for an initial payment of
$175,000 plus milestone payments totaling an additional
$525,000. Included in the March 1995 results is the initial
payment of $175,000. The balance of $525,000 is being held
in escrow and is included in Prepaid Expenses and Deposits in
the accompanying balance sheet (Form OPR-1). The July 1995
results include an accrual for $175,000 for the first milestone
payment, although the payment from the escrow account to BASF has
not occurred since the material has not yet been delivered.
5. In September 1992, the Company purchased a 15% interest in
ImmuCell Corporation for $600,000, and had advanced $120,000
to ImmuCell between June 1993 and April 1994. As a result of
negotiations with ImmuCell in September 1994, the carrying
value of the Company's investment was reduced by $250,000 to
reflect an estimate of the net realizable value. In November
1994, the carrying value of the investment was further reduced
to $308,571, which the Company received in December 1994 from
ImmuCell to purchase all of the shares owned by the Company.
The $120,000 advance was paid in full in December 1994.
6. On October 27, 1994, the Company's plan to institute a
retention bonus plan for some of its employees was approved
by the United States Bankruptcy Court for the District of
Massachusetts. The plan called for bonuses to be paid in
stock of the reorganized Company upon emergence from Chapter
11 reorganization. As of August 31, 1995, the Company has
recorded compensation expense of $1,476,157, which is a
non-cash expense.
7. On July 7, 1994, the date of the Company's Chapter 11 filing, it
had a $1,007,228 note payable to Fleet Credit Corporation (Fleet)
secured by $1,025,553 of certificates of deposit pledged to
Fleet. The certificates of deposit matured and were used to
liquidate the debt in accordance with relief from stay
granted by the Court. Included in the Company's short-term
investment balances for July 7, July 31, and August 31, 1994 were
$1,025,553 of CD's pledged to Fleet Credit Corporation.
8. On March 9, 1995, an Adversary Proceeding No. 95-4074 was
commenced in the United States Bankruptcy Court, District of
Massachusetts, Western Division, by Institut Pasteur and
Genetic Systems Corporation alleging patent infringement and
asking for damages and injunctive relief. The Company filed
an answer and counterclaim denying the plaintiffs' allegations
and alleging a breach by Institut Pasteur of its license agreement
with the Company. On September 6, 1995, the United States
Bankruptcy Court upheld the Company's license under two patents
issued to Institut Pasteur to commercialize diagnostic tests for
the HIV-2 strain of the AIDS virus. The Court also ruled that the
Company's HIV-1 Western blot confirmatory test for HIV-1 infringes
a third patent issued to Institut Pasteur, and enjoined the Company
from the manufacture and sale of the HIV-1 Western blot test. The
Company has appealed the portion of the opinion relating to the
patent covering the HIV-1 Western blot test. The Company is also
seeking to obtain a license to the patent from Institut Pasteur.
Although its 1994 audited financial statements have not been
finalized, the Company's preliminary and unaudited reports show
that the HIV-1 Western blot test accounted for less than 15% of
the Company's diagnostic revenues in 1994.
